cas 444289-05-8|| where to buy 3-[7-(aminomethyl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione;hydrochloride

Produktname:3-[7-(aminomethyl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione;hydrochloride

IUPAC Name:3-[4-(aminomethyl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione hydrochloride

: CAS：444289-05-8; Molekulare Formel：C14H16ClN3O3; Reinheit：95%+

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM340808-100mg	in stock	ƴǸƚ
CM340808-250mg	in stock	ħǸŮ
CM340808-1g	in stock	ŮƴŮ
CM340808-5g	in stock	ħħħƚ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 444289-05-8 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:444289-05-8; Molekulare Formel:C14H16ClN3O3; Schmelzpunkt:-; SMILES-Code:O=C(C(N1CC2=C(C=CC=C2CN)C1=O)CC3)NC3=O.[H]Cl; Dichte:

: Katalognummer:CM340808; Molekulargewicht:309.75; Siedepunkt:; Mdl-Nr.:; Lagerung:

: PROTAC-E3 Ligase Ligands; Bifunctional degrader molecules, also called proteolysis-targeting chimeras (PROTACs), are a new modality of chemical tools and potential therapeutics to understand and treat human disease. A required PROTAC component is a ligand binding to an E3 ubiquitin ligase, which is then joined to another ligand binding to a protein to be degraded via the ubiquitin–proteasome system. The advent of nonpeptidic small-molecule E3 ligase ligands revolutionized the field and ushered in the design of drug-like PROTACs with potent and selective degradation activity.; PROTAC-E3 Ligase Ligands | PROTACs | Bifunctional Degrader Molecules; Proteolysis-Targeting Chimeras | PROTAC-E3 Ligase Ligands | PROTACs | Bifunctional Degrader Molecules; PROTAC (Proteolysis-Targeting Chimeras) is a promising approach in drug discovery that involves the use of small molecules to target specific proteins for degradation by the cellular machinery.